Merck (MKGAY.PK) said fiscal 2021 was a year of record growth and margin expansion. Life Science was the main growth engine in 2021. For 2022, the company expects strong organic growth of net sales and EBITDA pre.
from RTT - Earnings https://ift.tt/vMrhfNA
via IFTTT
No comments:
Post a Comment